BREAKING NEWS! iTeos Therapeutics closes $125 Million Series B2 Financing iTeos Therapeutics, biotech company in our Walloon ecosystem, raised $125 million to support the clinical development of its two innovative cancer immunotherapy programs. Biotech company iTeos Therapeutics announced Wednesday that it has closed a $125 million Series B2 financing. Proceeds…
Authorisation scheme for the export of medical equipment from the EU Export outside the EU of the listed medical devices is now subject to a prior authorisation regime. Discover here the guidance note to Member States related to Commission implementing Regulation (EU) 2020/402 making the exportation of certain products subject to the…
Events and working process : update COVID-19 We will keep you posted on any further development! In the current environment, our priority is to reduce the risk of infection for our members, partners and employees. In order to eliminate any risk, BioWin events planned for March and April 2020 have been cancelled or postponed. We’ll keep you…
Ayming Belgium becomes the first partner of BioWin This novel cooperation enables the health cluster of Wallonia to supplement and strengthen its offer of support to the ecosystem stakeholders To support the growth of its members on specific aspects relating to their development, BioWin wishes to cooperate more proactively with its “associate” members, service companies…
BioWin is launching the 30th Competitive Cluster call for R&I projects Submit your letter of intent until January 27, 2020 BioWin is launching the 30th Competitive Cluster call for R&I projects. Letters of Intent can be submitted until January 27, 2020. If you have any question, please contact the R&I department ! Documents (only…
Bioxodes announces the initiation of a double blind, placebo controlled, single ascending dose phase I trial Bioxodes announces on October, 15 obtaining the authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers Ir-CPI is a potential best-in-class antithrombotic drug having an innovative mechanism of action (coagulation factors XIIa/XIa inhibition) to reduce…
Business Village Ecolys
Avenue d’Ecolys 2
5020 Namur (Belgium)
Email : contact@biowin.org
VAT BE 0882.768.591
Website by Monkeys not Donkeys
© 2024 BioWin.
